ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma
SSRN Electronic Journal
◽
10.2139/ssrn.3427299
◽
2019
◽
Author(s):
Brian Rini
◽
Sumanta K. Pal
◽
Bernard J. Escudier
◽
Michael B. Atkins
◽
Thomas E. Hutson
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Open Label
◽
Phase 3
◽
Open Label Study
◽
Label Study
Download Full-text
Related Documents
Cited By
References
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
The Lancet Oncology
◽
10.1016/s1470-2045(19)30735-1
◽
2020
◽
Vol 21
(1)
◽
pp. 95-104
◽
Cited By ~ 22
Author(s):
Brian I Rini
◽
Sumanta K Pal
◽
Bernard J Escudier
◽
Michael B Atkins
◽
Thomas E Hutson
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Open Label
◽
Phase 3
◽
Open Label Study
◽
Label Study
◽
Randomised Controlled
Download Full-text
Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Annals of Translational Medicine
◽
10.21037/atm.2020.03.217
◽
2020
◽
Vol 8
(16)
◽
pp. 1037-1037
Author(s):
Mary E. Westerman
◽
Christopher G. Wood
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Open Label
◽
Phase 3
◽
Open Label Study
◽
Label Study
◽
Editorial Commentary
◽
Randomised Controlled
Download Full-text
A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma
Clinical Genitourinary Cancer
◽
10.1016/j.clgc.2013.11.007
◽
2014
◽
Vol 12
(3)
◽
pp. 167-177.e2
◽
Cited By ~ 19
Author(s):
David S. Hong
◽
Michael S. Gordon
◽
Wolfram E. Samlowski
◽
Razelle Kurzrock
◽
Nizar Tannir
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Phase I
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Open Label
◽
Open Label Study
◽
Label Study
Download Full-text
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Journal of Clinical Oncology
◽
10.1200/jco.2018.36.15_suppl.tps4598
◽
2018
◽
Vol 36
(15_suppl)
◽
pp. TPS4598-TPS4598
◽
Cited By ~ 16
Author(s):
Toni K. Choueiri
◽
Andrea B. Apolo
◽
Thomas Powles
◽
Bernard Escudier
◽
Osvaldo Rudy Aren
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Open Label
◽
Phase 3
◽
Open Label Study
◽
Label Study
Download Full-text
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
Annals of Oncology
◽
10.1093/annonc/mdq651
◽
2011
◽
Vol 22
(8)
◽
pp. 1812-1823
◽
Cited By ~ 97
Author(s):
J. Beck
◽
G. Procopio
◽
E. Bajetta
◽
U. Keilholz
◽
S. Negrier
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Community Settings
◽
Open Label
◽
Open Label Study
◽
Label Study
◽
Expanded Access
◽
Diverse Community
Download Full-text
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(21)00693-8
◽
2022
◽
Author(s):
David Cella
◽
Robert J Motzer
◽
Cristina Suarez
◽
Steven I Blum
◽
Flavia Ejzykowicz
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Patient Reported Outcomes
◽
Advanced Renal Cell Carcinoma
◽
First Line
◽
Open Label
◽
Phase 3
◽
Patient Reported
Download Full-text
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
Cancer
◽
10.1002/cncr.33033
◽
2020
◽
Vol 126
(18)
◽
pp. 4156-4167
◽
Cited By ~ 6
Author(s):
Robert J. Motzer
◽
Bernard Escudier
◽
Saby George
◽
Hans J. Hammers
◽
Sandhya Srinivas
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Long Term Follow Up
Download Full-text
254 A SUBANALYSIS OF PATIENTS WITH AND WITHOUT PRIOR NEPHRECTOMY IN A LARGE OPEN-LABEL, NON-COMPARATIVE PHASE 3 EUROPEAN ADVANCED RENAL CELL CARCINOMA (RCC) SORAFENIB STUDY (EU-ARCCS)
European Urology Supplements
◽
10.1016/s1569-9056(09)60259-1
◽
2009
◽
Vol 8
(4)
◽
pp. 184
◽
Cited By ~ 1
Author(s):
M. Staehler
◽
G. Procopio
◽
U. Keilholz
◽
S. Negrier
◽
C. Szczylik
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Open Label
◽
Phase 3
Download Full-text
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Cancer Chemotherapy and Pharmacology
◽
10.1007/s00280-005-0070-z
◽
2005
◽
Vol 57
(4)
◽
pp. 533-539
◽
Cited By ~ 38
Author(s):
Monika Jermann
◽
Rolf A Stahel
◽
Marc Salzberg
◽
Thomas Cerny
◽
Markus Joerger
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Phase Ii
◽
Renal Cell
◽
Locally Advanced
◽
Open Label
◽
Open Label Study
◽
Label Study
Download Full-text
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(16)30107-3
◽
2016
◽
Vol 17
(7)
◽
pp. 917-927
◽
Cited By ~ 446
Author(s):
Toni K Choueiri
◽
Bernard Escudier
◽
Thomas Powles
◽
Nizar M Tannir
◽
Paul N Mainwaring
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close